Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A
Abstract
The goal is to evaluate the extended follow-up of the CYCLOFA-LUNE trial, a randomised prospective trial comparing to sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on Cyclophosphamide (CPH) or Cyclosporine (CyA). Data for kidney function, and adverse events were collected by a cross-sectional survey for 38 a 40 patients initially randomised in the CYCLOFA-LUNE trial.
The median follow up time was 7.7 years (range 5.0-10.3). Rates of renal impairment and end stage renal disease, and adverse events (death, cardiovascular event, tumor, premature menopause) did not differ between the CPH and CyA group, nor did mean serum creatinine, 24 h. proteinura, and SLICC damage score at last follow-up.These results are suggesting that an immunosuppressive regimen based on CyA achieved similar clinical results to that based on CPH in the very long term.